×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Hormone Sensitive Prostate Cancer Market

ID: MRFR/HC/35954-HCR
100 Pages
Rahul Gotadki
October 2025

Informe de investigación de mercado de cáncer de próstata sensible a hormonas por tipo de tratamiento (terapia hormonal, quimioterapia, radioterapia, inmunoterapia), por método de diagnóstico (biopsia, pruebas de imagen, análisis de sangre, análisis de orina), por etapa del cáncer (localizado, localmente avanzado, metastásico), por grupo de edad del paciente (menores de 50 años, 50-65 años, mayores de 65 años) y por región (América del Norte, Europa, América del Sur, Asia Pacífico, Medio Oriente) y África) - Previsión hasta 2034

Compartir
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hormone Sensitive Prostate Cancer Market Infographic
Purchase Options

Hormone Sensitive Prostate Cancer Market Resumen

Las empresas clave en el mercado Hormone Sensitive Prostate Cancer Market incluyen

Alcance del informe

Deja un comentario

FAQs

What is the projected market valuation for the Hormone-Sensitive Prostate Cancer Market in 2035?

The projected market valuation for the Hormone-Sensitive Prostate Cancer Market in 2035 is 31.16 USD Billion.

What was the market valuation for the Hormone-Sensitive Prostate Cancer Market in 2024?

The market valuation for the Hormone-Sensitive Prostate Cancer Market in 2024 was 17.78 USD Billion.

What is the expected CAGR for the Hormone-Sensitive Prostate Cancer Market from 2025 to 2035?

The expected CAGR for the Hormone-Sensitive Prostate Cancer Market during the forecast period 2025 - 2035 is 5.23%.

Which companies are considered key players in the Hormone-Sensitive Prostate Cancer Market?

Key players in the Hormone-Sensitive Prostate Cancer Market include Astellas Pharma, Bayer AG, Johnson & Johnson, Sanofi, Pfizer Inc., Novartis AG, Merck & Co., Eli Lilly and Company, and Amgen Inc.

What segment of the Hormone-Sensitive Prostate Cancer Market is projected to have the highest valuation by 2035?

The Hormonal Therapy segment is projected to reach a valuation of 10.5 USD Billion by 2035.

How does the market valuation for chemotherapy compare to hormonal therapy in 2035?

By 2035, the market valuation for chemotherapy is expected to be 6.5 USD Billion, significantly lower than the 10.5 USD Billion projected for hormonal therapy.

What is the projected market size for blood tests in the diagnosis of hormone-sensitive prostate cancer by 2035?

The projected market size for blood tests in the diagnosis of hormone-sensitive prostate cancer by 2035 is 9.05 USD Billion.

What is the expected market size for the metastatic stage of cancer by 2035?

The expected market size for the metastatic stage of cancer by 2035 is 12.16 USD Billion.

Which age group is projected to have the highest market valuation in the Hormone-Sensitive Prostate Cancer Market by 2035?

The age group over 65 is projected to have the highest market valuation of 15.08 USD Billion by 2035.

What is the projected valuation for imaging tests in the diagnosis of hormone-sensitive prostate cancer by 2035?

The projected valuation for imaging tests in the diagnosis of hormone-sensitive prostate cancer by 2035 is 7.56 USD Billion.

Descargar muestra gratis

Complete el formulario a continuación para recibir una muestra gratuita de este informe

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions